Reply to Vincenza Conteduca, Cristian Lolli, and Ugo De Giorgi's Letter to the Editor re: Pasquale Rescigno, David Lorente, Diletta Bianchini, et al. Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate Cancer. Eur Urol 2016;70:724-31.
作者信息
Rescigno Pasquale, de Bono Johann S
机构信息
The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Sutton, UK.
The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Sutton, UK.
出版信息
Eur Urol. 2016 Dec;70(6):e170-e171. doi: 10.1016/j.eururo.2016.05.029. Epub 2016 May 27.
PMID:27240941
Abstract
摘要
相似文献
1
Reply to Vincenza Conteduca, Cristian Lolli, and Ugo De Giorgi's Letter to the Editor re: Pasquale Rescigno, David Lorente, Diletta Bianchini, et al. Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate Cancer. Eur Urol 2016;70:724-31.
Eur Urol. 2016 Dec;70(6):e170-e171. doi: 10.1016/j.eururo.2016.05.029. Epub 2016 May 27.
2
Re: Pasquale Rescigno, David Lorente, Diletta Bianchini, et al. Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate Cancer. Eur Urol 2016;70:724-31.
Eur Urol. 2016 Dec;70(6):e168-e169. doi: 10.1016/j.eururo.2016.05.028. Epub 2016 May 30.
3
Reply to Vincenza Conteduca, Giorgia Gurioli, and Ugo De Giorgi's Letter to the Editor re: Niven Mehra, David Dolling, Semini Sumanasuriya, et al. Plasma Cell-free DNA Concentration and Outcomes from Taxane Therapy in Metastatic Castration-resistant Prostate Cancer from Two Phase III Trials (FIRSTANA and PROSELICA). Eur Urol. In press. https://doi.org/10.1016/j.eururo.2018.02.013.
Eur Urol. 2018 Sep;74(3):e69-e70. doi: 10.1016/j.eururo.2018.05.016. Epub 2018 Jun 1.
4
Re: Prostate-Specific Antigen Decline after 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-Resistant Prostate Cancer.
J Urol. 2016 Jul;196(1):103. doi: 10.1016/j.juro.2016.04.040. Epub 2016 Apr 14.
5
Reply to Kevin Lu's Letter to the Editor re: Orazio Caffo, Ugo De Giorgi, Lucia Fratino, et al. Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre Study. Eur Urol 2015;68:147-53.
Eur Urol. 2015 Dec;68(6):e132-3. doi: 10.1016/j.eururo.2015.08.018. Epub 2015 Aug 28.
6
Reply to Giandomenico Roviello, Daniele Generali, and Roberto Petrioli's Letter to the Editor re: Johann S. de Bono, Matthew R. Smith, Fred Saad, et al. Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2016.06.033.
Eur Urol. 2017 Feb;71(2):e56. doi: 10.1016/j.eururo.2016.08.011. Epub 2016 Aug 17.
7
Reply to Robert J. van Soest and Ronald de Wit's Letter to the Editor re: Johann S. de Bono, Matthew R. Smith, Fred Saad, et al. Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2016.06.033.
Eur Urol. 2017 Jan;71(1):e11. doi: 10.1016/j.eururo.2016.10.005. Epub 2016 Oct 14.
8
Comment on: "Modeling the Relationship between Exposure to Abiraterone and Prostate-Specific Antigen Dynamics in Patients with Metastatic Castration-Resistant Prostate Cancer".
Clin Pharmacokinet. 2017 Feb;56(2):211-212. doi: 10.1007/s40262-016-0468-2.
9
Re: Orazio Caffo, Ugo De Giorgi, Lucia Fratino, et al. Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre Study. Eur Urol 2015;68:147-53.
Eur Urol. 2015 Dec;68(6):e129-31. doi: 10.1016/j.eururo.2015.08.017. Epub 2015 Aug 28.
10
Reply to Ugo De Giorgi, Vincenza Conteduca, and Emanuela Scarpi's Letter to the Editor re: Marzia Del Re, Elisa Biasco, Stefania Crucitta, et al. The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients. Eur Urol 2017;71:680-7.
Eur Urol. 2018 Jan;73(1):e11-e12. doi: 10.1016/j.eururo.2017.07.034. Epub 2017 Aug 9.
Zotero 插件